Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Infinium PharmachemNSE:INFINIUM +1.70%86 3-Year ROIIC % is 4.08 as of Mar. 2026, which is 65% below its 10-year median of 11.73. GuruFocus rates NSE:INFINIUM with a GF Score™ of 86/100 and a GF Value™ of ₹308.29 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,528 Chemicals companies, Infinium Pharmachem ranks better than 57.98% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Infinium Pharmachem's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 4.08%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Infinium Pharmachem's 3-Year ROIIC % or its related term are showing as below:
NSE:INFINIUM's 3-Year ROIIC % is ranked better than 57.98% of 1528
companies
in the Chemicals industry
Industry Median: 0.07
vs NSE:INFINIUM: 4.08
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Infinium Pharmachem 3-Year ROIIC % Related Terms
Infinium Pharmachem 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Infinium Pharmachem's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Infinium Pharmachem's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Infinium Pharmachem 3-Year ROIIC % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Infinium Pharmachem's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Infinium Pharmachem's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Infinium Pharmachem (NSE:INFINIUM) has a 3-Year ROIIC % of 4.08 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Infinium Pharmachem and its competitors. This is 65% below median its historical median of 11.73. Over the past decade, Infinium Pharmachem's 3-Year ROIIC % has ranged from 1.42 to 24.56. According to the industry distribution chart, Infinium Pharmachem ranks #642 out of 1528 companies in the Chemicals industry, placing it in the top 42%.
Is Infinium Pharmachem's 3-Year ROIIC % too high?
Infinium Pharmachem's current 3-Year ROIIC % of 4.08 is 65% below median its 10-year median of 11.73. Over the past 10 years, this metric has ranged from a low of 1.42 to a high of 24.56. The Chemicals industry median 3-Year ROIIC % is 0.07. Infinium Pharmachem's value of 4.08 is 5728.6% above this industry median. Based on the distribution chart, Infinium Pharmachem ranks #642 out of 1528 companies in the Chemicals industry, which is above the industry midpoint. Overall, Infinium Pharmachem has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Infinium Pharmachem's 3-Year ROIIC % compare to DOW?
According to the Chemicals industry distribution chart, Infinium Pharmachem ranks #642 out of 1528 companies for 3-Year ROIIC %. This puts Infinium Pharmachem in the upper half of its industry. The industry median 3-Year ROIIC % is 0.07. Infinium Pharmachem's value of 4.08 is 5728.6% above this benchmark. Historically, Infinium Pharmachem's own 3-Year ROIIC % has ranged from 1.42 to 24.56 over the past decade. While the company's 10-year median is 11.73 vs. the industry median of 0.07, Infinium Pharmachem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Chemicals company?
The median 3-Year ROIIC % among Chemicals companies is 0.07, based on 1,528 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Infinium Pharmachem's current 3-Year ROIIC % of 4.08 is 5728.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Infinium Pharmachem and its competitors. For the Chemicals industry, the median 3-Year ROIIC % is 0.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Infinium Pharmachem's current 3-Year ROIIC % is 4.08, which is 65% below median its own 10-year median of 11.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infinium Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Infinium Pharmachem (NSE:INFINIUM) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹308.29, compared to a current price of ₹233.75 — trading 24.2% below its estimated fair value. The current 3-Year ROIIC % is 4.08, which is 65% below median its 10-year median of 11.73 and 5728.6% above the Chemicals industry median of 0.07. Infinium Pharmachem's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Infinium Pharmachem (NSE:INFINIUM), the current 3-Year ROIIC % is 4.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Infinium Pharmachem (NSE:INFINIUM) Overvalued in 2026?
Based on GuruFocus' analysis, Infinium Pharmachem stock appears to be undervalued.
The current stock price of ₹233.75 is trading 24.2% below its estimated GF Value™ of ₹308.29.
GuruFocus considers Infinium Pharmachem to be Modestly Undervalued.
Key valuation signals for NSE:INFINIUM:
3-Year ROIIC %: 4.08 (65% below median its 10-year median of 11.73)
GF Value™: ₹308.29 vs. price of ₹233.75 (24.2% below fair value)
Industry Position: 5728.6% above the Chemicals median (#642 of 1528)
No single metric tells the full story. See the NSE:INFINIUM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Infinium Pharmachem Ltd is engaged in the business of manufacturing and supplying Iodine, Iodine Derivatives and Active Pharmaceutical Ingredients (APIs). It provides fully integrated customized services from R & D to Commercial scale manufacturing and packaging for its products to the Pharmaceutical, Agrochemical, Nutraceutical, Speciality Chemicals and various other chemicals Industries.
86GF Score
Get the complete analysis for NSE:INFINIUM
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFINIUM has been successfully added to your 
